Introduction
Diabetes is now the most common cause of endstage renal disease (ESRD) in the United States, in part due to the increased prevalence of type II diabetes. 1, 2 Approximately 40% of new cases of ESRD occur in patients with diabetic nephropathy. The earliest clinical stage of nephropathy is the presence of low levels of albumin in the urine (urinary albumin excretion X30 and o299 mg/day) referred to as microalbuminuria. 1 Albuminuria is not only a marker for development of nephropathy in type II diabetes but also for increased cardiovascular disease (CVD) morbidity and mortality. 3 Studies have shown that patients with type II diabetes and microalbuminuria have a total mortality of approximately 8% and a CVD mortality of 4% annually, values up to four times higher than those seen in patients without microalbuminuria. 4, 5 As part of the metabolic syndrome of insulin resistance, obesity, and dyslipidaemia, hypertension is present in up to 60% of patients with type II diabetes. 2 High systolic blood pressure (SBP) is an independent risk factor for ESRD and death, and any level of SBP above 140 mmHg significantly increases risk for renal disease progression compared with levels below 130 mmHg. 6 These findings strongly support intervention to reduce all CVD risk factors, especially aggressive blood pressure (BP) control, for patients with diabetes at high risk for nephropathy.
Recent studies have demonstrated the importance of inhibition of the renin-angiotensin-aldosterone (RAA) system to reduce the risk and slow down the progression of renal disease.
1 Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), either as monotherapy or in combination, are first-line agents for delaying the progression of diabetic nephropathy. The recommendations in support of ACE inhibitors or ARBs for type II diabetes are based on large, controlled clinical trials. 2, [7] [8] [9] [10] Both ACE inhibitors and ARBs have shown positive effects against markers of renal disease progression or in risk reduction for overt nephropathy and ESRD in patients with type II diabetes. Reduction in proteinuria that is partially independent of BP reduction has been demonstrated in MARVAL (MicroAlbuminuria Reduction with VALsartan). 11 The optimal doses employed for renal protection may be greater than those used for lowering BP. 12 However, there are scant data with ACE inhibitors from outcome trials to evaluate their effects with other classes of antihypertensive agents on hard end points such as ESRD.
The goal BP for patients with diabetes is o130/ 80 mmHg. Achieving this lower BP goal is difficult and virtually impossible to achieve with monotherapy. 2, 13, 14 The majority of patients usually require the addition of multiple antihypertensive medications to achieve this lower BP goal. Indeed, in the three outcome studies on renal protection using ARBs, [8] [9] [10] the majority of patients received three or more drugs in combination; in two of these studies, the mean final BP control to the recommended goal (o130/80 mmHg) was not achieved. 9, 10 Combinations of different antihypertensive drugs (with complementary mechanisms of action) are necessary to achieve the appropriate lower BP goals in patients with type II diabetes. Utilizing combination antihypertensive therapy as initial therapy is an important direction for trial design to take in order to evaluate renal protection in hypertensive diabetic patients. More clinical trials are needed to evaluate whether specific management to reduce albuminuria with ACE inhibitors will be beneficial in type II diabetes. 15 It is possible that combination treatments may have additive or synergistic renal-protective effects other than BP control.
The GUARD trial
The GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) trial is designed to compare the efficacy and safety of two fixed-dose combination antihypertensive regimens, amlodipine besylate/benazepril hydrochloride (HCl) and benazepril HCl/hydrochlorothiazide (HCTZ), as initial therapy in patients with type II diabetes, albuminuria, and hypertension. The GUARD trial utilizes initial therapy with two drugs, as opposed to initial therapy with one drug and the addition of other medications as needed, to achieve a BP goal of o130/80 mmHg.
Materials and methods
The GUARD trial is an ongoing, 1-year, randomized, multicentre, double-blind, parallel-group study comparing the efficacy and safety of initial combination antihypertensive therapy with amlodipine besylate/benazepril HCl 5/20, 5/40, and 10/40 mg vs benazepril HCl/HCTZ 20/12.5, 40/12.5, and 40/ 25 mg in hypertensive patients with type II diabetes, albuminuria, and hypertension ( Figure 1 ).
The primary objective is to compare the change from baseline in the urinary albumin to creatinine (Ualb:Cr) ratio after 1 year of active treatment. Secondary objectives are to compare the proportion of patients who develop overt diabetic nephropathy as determined by a Ualb:Cr ratio X300 mg/mg Figure 1 The GUARD study design.
Combination regimens to reduce albuminuria GL Bakris et al creatinine after 1 year of active treatment; the change from baseline in the ratio of Ualb:Cr ratio to estimated glomerular filtration rate (EGFR); the change from baseline in insulin resistance; the change from baseline in plasma B-type natriuretic peptide (BNP); 16 and the change from baseline in highly sensitive C-reactive protein (Hs-CRP).
Eligible patients include men and women aged 21-85 years with type II diabetes mellitus, albuminuria, and hypertension. The presence of albuminuria has been determined by at least two of three consecutive morning urine specimens with a Ualb:Cr ratio between 20 and 500 mg/mg creatinine (inclusive).
A total of 334 patients (167 per arm) will be randomized ( Figure 1 ). The total study duration is approximately 59 weeks. The evaluation and visit schedules for the pre-study, placebo run-in, and active treatment phases are shown in Tables 1 and 2 .
Randomization will be performed by an automated randomized assignment system. The randomization of patients will be stratified by assigning random numbers to each of the following three strata based on high, medium, and low levels of baseline Ualb:Cr ratio. High is defined as 211-500 mg/mg creatinine (inclusive); medium as 121-210 mg/mg creatinine (inclusive); and low as 20-120 mg/mg creatinine (inclusive).
The first 4-week phase of the study will screen patients for eligibility. Patients will be withdrawn from therapy with ACE inhibitors and ARBs.
Following will be a 3-week placebo run-in phase, in which all antihypertensive agents will be discontinued. The third phase consists of a 52-week active treatment phase, in which treatment will be titrated to reach the target BP goal of o130/ 80 mmHg. Throughout the study, patients will receive appropriate treatment for diabetes at the discretion of the physician.
Active treatment phase
All patients must have a mean SBP of X135 and o180 mmHg and/or a mean diastolic blood pressure (DBP) of X85 and o110 mmHg to enter into the active treatment phase. At Week 0, patients will be randomized to receive dose level 1 (amlodipine besylate/benazepril HCl 5/20 mg or benazepril HCl/ HCTZ 20/12.5 mg) for 4 weeks to achieve the target BP of o130/80 mmHg. At Week 4, patients who do not achieve the target BP will be titrated to dose level 2 (amlodipine besylate/benazepril HCl 5/40 mg or benazepril HCl/HCTZ 40/12.5 mg) for 4 weeks. At Week 8, patients who do not meet the target BP will be titrated to dose level 3 (amlodipine besylate/ benazepril HCl 10/40 mg or benazepril HCl/HCTZ 40/25 mg). At Week 12 and all subsequent visits, patients who do not meet the target BP will be titrated to the next dose level; patients receiving dose level 3 will receive add-on antihypertensive therapy to dose level 3. Three consecutive urine collections will be performed during Week -2 to Week -1 to confirm that the Ualb:Cr ratios meet the eligibility criteria for randomization at Visit 6 (Week 0).
Statistical methods
All statistical tests in this noninferiority trial will be conducted against a two-sided alternative hypothesis employing a significance level of 0.05. Data will be summarized with respect to demographic and baseline characteristics, efficacy, and safety measurements. All randomized patients who take at least one dose of study medication will be included in the safety analysis. The intent-to-treat population, consisting of all randomized patients who take at least one dose of study medication and from whom at least one post-baseline efficacy measurement is obtained, will be included in the efficacy analysis. The study is based on the hypothesis that the CCB/ACE inhibitor is either comparable or superior to the ACE inhibitor/diuretic treatment regimen on the primary efficacy variable: the change from baseline in the Ualb:Cr ratio at Week 52. The null hypothesis that the treatment effect of the CCB/ACE inhibitor treatment regimen with respect to the primary efficacy variable is within 0.04 of the ACE/diuretic treatment regimen will be tested against the alternative hypothesis that the treatment effect of the CCB/ACE inhibitor treatment regimen is not less than that of the ACE inhibitor/diuretic treatment regimen by 0.04 or more.
For testing the hypothesis of noninferiority of the CCB/ACE inhibitor treatment regimen and the ACE inhibitor/diuretic treatment regimen, a one-sided test will be performed at the 2.5% level of significance (or equivalently, a 97.5% one-sided confidence interval for the difference will be used). Tests for the superiority of the CCB/ACE inhibitor treatment regimen vs the ACE inhibitor/diuretic treatment regimen will be based on the null hypothesis, and a two-sided test will be made at the 5% significance level. An analysis of covariance will be used with baseline assessment as a covariate, and treatment and centre as factors in the model; 95% confidence interval for the difference between the two treatment groups will also be reported based on the fitted linear model. If the assumptions of the parametric test are not satisfied, then a nonparametric test (ie, Wilcoxon rank-sum test) will be used to compare the two treatment groups.
The proportion of patients that develop overt nephropathy will be analysed using the CochranMantel-Haenszel (CMH) w 2 -test, adjusting for centre. The analyses for the primary and secondary efficacy variables will be performed using the patient's last nonmissing postbaseline assessment (ie, last observation carried forward).
Sample size
The sample size calculation (performed using nQuery Advisor, Statistical Solutions, Saugus, MA, USA) was determined based on 90% power, 
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assuming no difference in change in Ualb:Cr ratio between the two active treatments, the noninferiority limit difference of 0.04 with a one-sided significance level of 2.5%, and allowing for a dropout rate of 20% after randomization. Thus, a sample size of approximately 334 randomized subjects (167 per arm) is necessary. This sample size also provides 490% power for the test of superiority at the two-sided significance level of 0.05, based on detecting at least a clinically meaningful difference of 0.05 in the change in Ualb:Cr ratio between the two treatment regimens.
Discussion
Most kidney disease worsens progressively over time. 17 Up to 10% of patients with type II diabetes and microalbuminuria develop diabetic nephropathy each year. 7, 8 In their 2-year study of 590 hypertensive patients with type II diabetes and microalbuminuria, Parving et al 8 noted that the Kaplan-Meier curves for the incidence of diabetic nephropathy in the placebo vs irbesartan 300 mg q.d. groups diverged at 3 months and continued to diverge, and that across the groups the steepest drop in GFR was seen in the first 3 months. Very early recognition and intervention can slow the onset and course of diabetic nephropathy in patients with diabetes and hypertension who are at high risk for renal complications. 1 In their recently published guidelines, the Working Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative recommends reducing proteinuria as a goal for antihypertensive therapy in patients with chronic kidney disease. 17 Pharmacologic inhibition of the RAA system has been shown to control BP, reduce albuminuria, and protect against progressive renal damage. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, the target-organ protection is attenuated when BP is not adequately controlled. 6 ACE inhibitors used as monotherapy do not adequately control hypertension in many cases, and three or more agents are usually required. Dihydropyridine CCBs should be considered as one of these agents because of their effectiveness in reducing BP. The use of fixed-dose combination therapy with a CCB/ACE inhibitor in type II diabetes has been shown in SHIELD (Study of Hypertension and the Efficacy of Lotrel in Diabetes) to have superior BP-lowering efficacy compared with conventional ACE inhibitor monotherapy. 18 
Conclusion
Information on optimal therapeutic strategies to prevent progression of kidney disease is of substantial importance. Ongoing and planned trials in hypertensive diabetic patients, such as GUARD, must consider both the importance of lowering BP and providing target-organ protection. The GUARD study will evaluate the optimal combination of the most commonly used antihypertensive drug classes-that is, ACE inhibitors, dihydropyridine CCBs, and diuretics-known to provide particular benefits to patients at risk for target-organ damage. Furthermore, the relationships between renal protection and markers of vascular inflammation and pressure/volume overload will be evaluated in this study. It is expected that the best combination therapy will provide optimal protection against the development of worsening kidney disease and improvement in the biomarker profile in the study population at high risk for the development of ESRD and death.
